Nuria Ribelles

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Missing data imputation using statistical and machine learning methods in a real breast cancer problem

José M. Jerez, Ignacio Molina, Pedro J. García-Laencina et al. · Artificial Intelligence in Medicine · 2010 · 587 citations

Engineering, Machine Learning, Data Mining +9

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

Miguel Martín, Monserrat Muñoz, A. Balil et al. · The Lancet Oncology · 2007 · 186 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +7

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco et al. · Annals of Oncology · 2023 · 183 citations · Full text

Medicine, Cancer Management, Cancer Registration +5

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5